SOST and cardiovascular disorder: Systemic sclerostin inhibition promotes vascular calcification and elevates inflammatory cytokine levels, further heightening cardiovascular disease risk.64 Consequently, bone-targeted Sost inhibition warrants careful consideration in treatment strategies.